Urologic oncology involves the diagnosis, comprehensive treatment, and follow-up of patients with cancers of the prostate, bladder, kidney, testicle, adrenal gland, penis and retroperitoneum. Numerous medical and surgical advances over the past several years have improved the treatments of malignancies, with earlier diagnosis, fewer treatment-related complications and side effects, and most importantly, more cures and enhanced survival in many cases.
Patients undergoing surgery for prostate cancer need no longer assume nor expect impotence as a result of "cutting the nerves." Refinements in the technique of "nerve-sparing" and "continence-sparing" radical prostatectomy can now deliver the best cancer therapy, along with fewer side effects than ever before.
Patients with bladder cancer who require cystectomy (removal of the bladder) can now be offered several options for urinary reconstruction which have eliminated the need for a permanent urinary ostomy (ileal conduit). These new techniques help dramatically improve both self-image and quality of life.
Similarly, numerous other advances and improvements have been developed for kidney cancer, testicular cancer and other urologic malignancies. Methodical and precise follow-up and proper management of cancer-related complications are also an integral component of comprehensive urologic oncology care. Familiarity with all of these treatment modalities, and the development of new innovations in cancer care are the basis of urologic oncology.
Nicholas T. Karanikolas, MD
Director of Urologic Oncology
Phone: (718) 226-6031
Board Certified, Urology
Associate Director, Division of Urology
Phone: (718) 226-2950
Minimally Invasive Surgery, Robotic/Laparoscopic Surgery & Renal Transplant Surgery
Phone: (718) 226-6461